News and Trends 20 Sep 2022
Positive results from Arecor Therapeutics’ clinical trial of rapid, concentrated insulin
Arecor Therapeutics today (September 20) announced positive results from a phase 1 clinical trial of its rapid, concentrated insulin product. The company’s candidate named AT278 is formulated using its Arestat technology and designed to significantly accelerate insulin absorption post injection. This is to enable more effective and convenient management of blood glucose levels in people […]